[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100545536":3},{"organization":4,"outcomesModule":7,"designInfo":45,"detailedDescription":33,"studyPopulation":48,"armGroups":33,"interventions":49,"overallOfficials":33,"centralContacts":33,"locations":54,"responsibleParty":78,"collaborators":33,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":33,"eligibilityCriteria":88,"healthyVolunteers":84,"sex":89,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":95,"studyType":96,"phases":33,"briefSummary":97,"conditions":98,"keywords":33,"overallStatus":57,"whyStopped":33,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"General Hospital of Shenyang Military Region","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":34},[9],{"measure":10,"description":11,"timeFrame":12},"Dynamic changes in serum biomarkers after endovascular treatment","These biomarkers will be identified based on proteomic methods","from the baseline to immediately, 30 minutes, 6 hours, and 24 hours after endovascular treatment",[14,18,20,22,26,28,31],{"measure":15,"description":16,"timeFrame":17},"favourable functional outcome, defined as modified Rankin Scale (mRS) 0-2","mRS ranges from 0-6, high score means poor outcome","90±7 days",{"measure":19,"description":16,"timeFrame":17},"excellent functional outcome, defined as modified Rankin Scale (mRS) 0-1",{"measure":21,"description":16,"timeFrame":17},"distribution of modified Rankin Scale (mRS) score",{"measure":23,"description":24,"timeFrame":25},"early neurological improvement, defined as 4 or more decrease in National Institute of Health stroke scale (NIHSS)","NIHSS ranges from 0-22, with high score meaning severe neurological deficit.","24±8 hours",{"measure":27,"description":24,"timeFrame":25},"changes in National Institute of Health stroke scale (NIHSS)",{"measure":29,"description":30,"timeFrame":25},"symptomatic intracranial hemorrhage (sICH)","sICH is defined as an increase in 4 or more points on the NIHSS",{"measure":32,"description":33,"timeFrame":17},"occurence of new stroke or other vascular events",null,[35,39,42],{"measure":36,"description":37,"timeFrame":38},"the association between cerebral circulation time (CCT) and clinical outcomes","CCT is defined as the time from the appearance of contrast at the siphon segment of the internal carotid to the end of the arterial phase during DSA on the anteroposterior and lateral image in anterior circulation LVO; clinical outcomes include changes in NIHSS and mRS","24±8 hours, 10±2 days, 90±7 days",{"measure":40,"description":41,"timeFrame":38},"the association between serum biomarkers and clinical outcomes","serum biomarkers include those in different timepoints or their dynamic changes; clinical outcomes include changes in NIHSS and mRS",{"measure":43,"description":44,"timeFrame":38},"the association between serum biomarkers and status of vessel recanalization","serum biomarkers include those in different timepoints or their dynamic changes; the status of vessel recanalization is determined by modified thrombolysis in cerebral infarction",{"allocation":33,"interventionModel":33,"interventionModelDescription":33,"primaryPurpose":33,"observationalModel":46,"timePerspective":47,"maskingInfo":33},"COHORT","PROSPECTIVE","Patients with acute anterior circulation large vessel occlusion within 24 hours of onset who will receive endovascular treatment",[50],{"type":51,"name":52,"description":53,"armGroupLabels":33,"otherNames":33},"PROCEDURE","endovascular treatment","all patients with anterior circulation large vessel occlusion will receive endovascular treatment.",[55],{"facility":56,"status":57,"city":58,"state":33,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"General Hospital of Northern Theater Command","RECRUITING","Shenyang","110840","China","CN",{"type":63,"coordinates":64},"Point",[65,66],123.43278,41.79222,{"lat":66,"lon":65},[69,74],{"name":70,"role":71,"phone":72,"phoneExt":33,"email":73},"Zi-Ai Zhao","CONTACT","86-2428897517","zhaoziai@hotmail.com",{"name":75,"role":71,"phone":76,"phoneExt":33,"email":77},"Yu Cui","86-24-28897499","cuiyu.spu@hotmail.com",{"type":79,"investigatorFullName":80,"investigatorTitle":81,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"PRINCIPAL_INVESTIGATOR","Hui-Sheng Chen","Director","100545536","change-in-serum-biomarkers-after-endovascular-treatment-for-acute-anterior-circulation-large-vessel-occlusion-100545536",false,"NCT06383182","Change in Serum Biomarkers After Endovascular Treatment for Acute Anterior Circulation Large Vessel Occlusion","Change in Serum Biomarkers After Endovascular Treatment for Acute Anterior Circulation Large Vessel Occlusion: a Prospective, Registry Study","Inclusion Criteria:\n\n1. Age: 18-80 years;\n2. Patients with acute anterior circulation large vessel occlusion within 24 hours of onset who will receive endovascular treatment;\n3. Pre-stroke mRS: 0-1;\n4. Baseline NIHSS: ≥6;\n5. Signed informed consent.\n\nExclusion Criteria:\n\n1. The presence of contraindications to internal jugular vein cannulation;\n2. Receiving intravenous thrombolysis;\n3. Haemorrhagic stroke (cerebral haemorrhage or subarachnoid haemorrhage);\n4. Coagulation disorders, systemic bleeding tendency, thrombocytopenia (\\\u003C100×109\u002FL);\n5. Severe cardiac, hepatic or renal insufficiency (ALT or AST elevated more than 2 times the upper limit of normal value, or serum creatinine elevated more than 1.5 times the upper limit of normal value or in need of dialysis) or other serious medical diseases;\n6. Severe uncontrolled hypertension (systolic blood pressure greater than 200 mmHg or diastolic blood pressure greater than 110 mmHg);\n7. Pregnant or lactating women;\n8. Other conditions who are not suitable for this trial by investigator.","ALL","18 Years","80 Years",{"count":93,"type":94},800,"ESTIMATED","90 Days","OBSERVATIONAL","Acute ischaemic stroke (AIS) results in high rates of neurological morbidity and mortality, especially in patients with large vessel occlusion (LVO). Endovascular therapy (EVT) has been approved as the most effective treatment for patients with LVO , but about half patients undergoing EVT did not achieve good outcome. The mechanisms of poor prognosis are complex. How to accurately identify serological biomarkers related to patients' clinical prognosis is an important research topic nowadays.",[99],"Ischemic Stroke","2026-09-15",{"date":102,"type":103},"2026-09-17","ACTUAL",{"date":105,"type":103},"2024-07-02",{"date":107,"type":94},"2027-12-30",{"name":5,"class":6},1]